Donohue, James F.
Kerwin, Edward
Sethi, Sanjay
Haumann, Brett
Pendyala, Srikanth
Dean, Lorna
Barnes, Chris N.
Moran, Edmund J.
Crater, Glenn http://orcid.org/0000-0002-1159-1323
Funding for this research was provided by:
Theravance Biopharma, Ireland Limited Inc. (Not applicable)
Article History
Received: 21 December 2018
Accepted: 11 September 2019
First Online: 30 October 2019
Ethics approval and consent to participate
: The trial was conducted in accordance with the principles of the International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guideline for good clinical practice [CitationRef removed], and the code of ethics of the World Medical Association’s Declaration of Helsinki [CitationRef removed], and all patients provided written informed consent.
: Not applicable
: B.H., S.P., L.D., E.J.M. and G.C. are current employees of Theravance Biopharma US, Inc.C.N.B was an employee of Theravance Biopharma US, Inc. at the time this study was conducted.J.F.D. is a consultant and advisory committee member for Mylan Inc., Theravance Biopharma, Sunovion Pharmaceuticals, AstraZeneca, and GSK.S.S. is a consultant and advisory committee member for Theravance Biopharma US, Inc., and received research support from Mylan Inc.E.K. has participated in consulting, advisory boards and speaker panels, or received travel reimbursement for Amphastar, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mylan, Novartis, Oriel, Pearl, Sunovion, Teva and Theravance Biopharma. He has conducted multi-center clinical research trials for approximately 40 pharmaceutical companies.